Negative Beta Glucan in ICU Patients

Status Completed

Clinical Trial Summary

This is a prospective study aimed at testing a strategy of early initiation of an antifungal agent to patients admitted to intensive care units (ICUs) at risk for invasive candidiasis. Score system have been developed to identify groups at very high risk for the development of candidemia/invasive candidiasis in the ICU. These scoring system have used clinical information with or without data on Candida colonization, and have shown reasonable correlation with candidemia/invasive candidiasis. More recently, a biomarker - detection of 1,3-beta-D-glucan in the serum - has been tested in the early diagnosis of candidiasis. The incorporation of biomarkers such as beta-D-glucan could help clinicians to select a group at higher risk for candidemia, and despite the fact that these tests may give false-positive results, their negative predictive value could be of great help.

Therefore, the objectives of this study are:

1. To assess the frequency of positive biomarkers in ICU patients at high risk to develop invasive candidiasis/candidemia;

2. To test the strategy of early discontinuation of antifungal therapy based on repeatedly negative blood cultures and 1,3 beta-D-glucan in the serum.

Clinical Trial Description

Entry criteria are: In the ICU for >2 days AND systemic antibiotics >2 days OR central venous catheter for >days AND at least two of the following: total parenteral nutrition, dialysis, surgery, pancreatitis, receipt of corticosteroids, receipt of other immunosuppressive agents. In addition, patients must have a clinical sign of infection (either one of the following): fever, hypothermia, hypotension, unexplained acidosis, or unexplained elevation in C-reactive protein.

Eligible patients will be enrolled after signing an informed consent and will have blood obtained for culture and determination of 1,3 beta-D-glucan serum levels for 3 days, and will start anidulafungin IV.

If all tests are negative, anidulafungin will be discontinued on day 4. If 1,3 beta-D-glucan is positive (>80 pg/ml) and / or blood cultures are positive for Candida species, anidulafungin will be continued for >14 days. ;

Study Design

Related Conditions & MeSH terms

Candidemia

Clinical Trial Details

NCT number	NCT01734525
Study type	Interventional
Source	Universidade Federal do Rio de Janeiro
Contact
Status	Completed
Phase	Phase 4
Start date	November 2012
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01982071` - A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia	Phase 4
Completed	`NCT02244606` - Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis	Phase 2
Completed	`NCT02163889` - Serial Therapeutic and Antifungal Monitoring Protocol
Recruiting	`NCT01438216` - Anidulafungin Pharmacokinetics in Intensive Care Unit Patients	N/A
Not yet recruiting	`NCT01249313` - Risk Factor and Outcome of Candidemia	N/A
Terminated	`NCT01213823` - Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins	Phase 4
Completed	`NCT00940017` - A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects	Phase 4
Completed	`NCT00105144` - Study of Micafungin in Patients With Invasive Candidiasis or Candidemia	Phase 3
Completed	`NCT03667690` - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis	Phase 3
Completed	`NCT03604705` - An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia	Phase 2
Completed	`NCT00607763` - Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Completed	`NCT00608335` - Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug	Phase 1
Recruiting	`NCT04147975` - Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood
Withdrawn	`NCT01622595` - UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients	N/A
Completed	`NCT03363841` - Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)	Phase 3
Completed	`NCT03799172` - Echinocandins Versus Azoles for Candidemia Treatment
Completed	`NCT01406093` - Early- and Late-onset Candidemia	N/A
Completed	`NCT00670657` - CRITIC - Treatment of Candidemia and Invasive Candidiasis	Phase 4
Completed	`NCT00113191` - Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants	N/A
Recruiting	`NCT04368559` - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.